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Background: This study was conducted to assess the prognostic value of the number of negative lymph nodes
(NLNs) in breast cancer patients with four or more positive lymph nodes after postmastectomy radiotherapy
(PMRT).
Methods: This retrospective study examined 605 breast cancer patients with four or more positive lymph nodes
who underwent mastectomy. A total of 371 patients underwent PMRT. The prognostic value of the NLN count in
patients with and without PMRT was analyzed. The log-rank test was used to compare survival curves, and Cox
regression analysis was performed to identify prognostic factors.
Results: The median follow-up was 54 months, and the overall 8-year locoregional recurrence-free survival (LRFS),
distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) were 79.8%, 50.0%, 46.8%,
and 57.9%, respectively. The optimal cut-off points for NLN count was 12. Univariate analysis showed that the
number of NLNs, lymph node ratio (LNR) and pN stage predicted the LRFS of non-PMRT patients (p < 0.05 for all).
Multivariate analysis showed that the number of NLNs was an independent prognostic factor affecting the LRFS,
patients with a higher number of NLNs had a better LRFS (hazard ratio = 0.132, 95% confidence interval = 0.032-0.547,
p =0.005). LNR and pN stage had no effect on LRFS. PMRT improved the LRFS (p < 0.001), DMFS (p = 0.018), DFS
(p = 0.001), and OS (p = 0.008) of patients with 12 or fewer NLNs, but it did not any effect on survival of patients with
more than 12 NLNs. PMRT improved the regional lymph node recurrence-free survival (p < 0.001) but not the chest wall
recurrence-free survival (p = 0.221) in patients with 12 or fewer NLNs.
Conclusions: The number of NLNs can predict the survival of breast cancer patients with four or more positive lymph
nodes after PMRT.
Keywords: Breast cancer, Mastectomy, Negative lymph nodes, Radiotherapy* Correspondence: baoyong@sysucc.org.cn; hezhy@sysucc.org.cn
†Equal contributors
2Department of Radiation Oncology, Collaborative Innovation Center of
Cancer Medicine, State Key Laboratory of Oncology in South China, Sun
Yat-sen University Cancer Center, Guangzhou 510060, People’s Republic of
China
Full list of author information is available at the end of the article
© 2014 Wu et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Wu et al. Radiation Oncology  (2014) 9:284 Page 2 of 9Background
The purpose of postmastectomy radiotherapy (PMRT) is
to improve survival by eliminating potential occult le-
sions in the chest wall and lymphatic drainage area. The
status of axillary lymph nodes is an important factor that
affects the choice to use PMRT. PMRT is a standard ad-
juvant postoperative therapy for patients with four or
more positive lymph nodes [1-3]. The local recurrence
rate (LRR) of patients with four or more positive lymph
nodes who did not receive PMRT was 11.9-59% [4-6].
Thus, about 40% of patients with four or more positive
lymph nodes do not benefit from PMRT. At present,
there is a trend for oncologists to use individualized treat-
ments for different breast cancer patients. However, it is
still difficult to predict which patients with four or more
positive lymph nodes will benefit from PMRT.
In breast cancer patients, there is a critical correlation
between the status and dissection of axillary lymph nodes,
especially with regard to the number of removed lymph
nodes (RLNs) [7,8]. The total number of RLNs includes
positive lymph nodes and negative lymph nodes (NLNs),
so this number may not be a reliable clinical indicator.
In addition, due to the different pathological features of
lymph nodes, there may be different numbers of occult
lesions in the different numbers of NLNs. In theory, re-
moval of more NLNs may reduce the overall risk of oc-
cult lesions and thereby improve patient survival. If the
number of NLNs is relatively small, the possible pres-
ence of occult lesions may increase the LRR. Previous
research reported that the number of NLNs might affect
the prognosis of breast cancer patients [9,10]. However,
the usefulness of the number of NLNs in predicting out-
come after PMRT has not yet been reported. We hypothe-
sized that the number of NLNs affects the LRR of breast
cancer patients with four or more positive lymph nodes
and thereby affects the outcome of PMRT. The current
study is a retrospective analysis that investigated the pre-
dictive value of the number of NLNs in breast cancer




We retrospectively evaluated 605 breast cancer pa-
tients who were received mastectomy at the Sun Yat-sen
University Cancer Center between January 1998 and
December 2007. All included patients were females who:
(i) had pathologically confirmed diagnoses of unilateral
invasive breast cancer; (ii) received mastectomy and ax-
illary lymph node dissection (at least I-II levels) with 10
or more lymph nodes; (iii) had stage pT1-4 N2-3 M0
cancer according to the 7th edition of the American
Joint Committee on Cancer/Union for International
Cancer Control (AJCC/UICC) tumor node metastasis(TNM) staging system; (iv) the tumor was completely
removed and the margins were negative; (v) no neoad-
juvant chemotherapy was administered before surgery,
and receive at least 4 cycles of postoperative adjuvant
chemotherapy; (vi) complete immunohistochemistry re-
sults including estrogen receptor (ER), progesterone re-
ceptor (PR), and human epidermal growth factor receptor
2 (HER2), and endocrine therapy was administered when
indicated.
Clinical and pathological factors and lymph node status
Patient clinicopathological and immunohistochemical fac-
tors including age, menstrual status, pT stage, pN stage,
NLN count, lymph node ratio (LNR), ER, PR, HER2,
breast cancer subtypes (BCS), and PMRT. ER and PR
positivity were defined by the presence of more than 1%
positive cells based on immunohistochemistry results;
HER2 positivity was defined as 3+ or 2+ with confirm-
ation by fluorescence in situ hybridization (FISH). The
BCS were not determined according to the criteria devel-
oped in the St. Gallen International Breast Cancer Confer-
ence because immunohistochemistry results for Ki-67
were not available for some patients [11]. Thus, the
categorization of BCS was based on ER, PR, and HER2
status as follows: luminal A (ER+ and/or PR+, and HER2-),
luminal B (ER+ and/or PR+, and HER2+), HER-2 + (ER-,
PR-, and HER2+), and triple negative (TN) (ER-, PR-, and
HER2-).
We identified the pT/pN stages according to the 7th
edition of the AJCC/UICC TNM staging system. Stage
pN2 was defined by metastases in 4–9 lymph nodes and
stage pN3 by metastases in 10 or more lymph nodes.
The number of removed NLNs was obtained by sub-
tracting the number of positive lymph nodes from the
total number of removed axillary lymph nodes. LNR
classifications were based on the report by Vinh-Hung
et al. [12] and our previously reported [13,14]. Patients
were classified into 3 groups with LNR 0.01-0.20, LNR
0.21 - 0.65, and LNR > 0.65.
Treatment
Adjuvant chemotherapy was administered to all patients
for a median of 6 cycles (range: 4–8 cycles), with 29 pa-
tients (4.8%) receiving a regimen consisting of cyclo-
phosphamide, methotrexate, and 5-fluorouracil (CMF),
and 576 (95.2%) receiving regimens with anthracycline
and/or taxane. All patients were recommended for PMRT,
but the patient made the final decision over whether to
proceed. Of the 234 patients (38.7%) did not receive
PMRT due to economic and social factors. A total of
371 patients (61.3%) received PMRT within 6 months
after surgery. The PMRT was delivered mainly to the
ipsilateral chest wall, supra- and infra-clavicular lymph
node regions. The total radiation dose was 46–50 Gy in
Table 1 Characteristics of breast cancer patients who
received and did not receive postmastectomy
radiotherapy
Characteristic n Without PMRT With PMRT p
(n = 234) (%) (n = 371) (%)
Age, years
<35 64 20 (8.6) 44 (11.9) 0.197
≥35 541 214 (91.4) 327 (88.1)
Menopausal status
Premenopausal 400 153 (65.4) 247 (66.6) 0.763
Postmenopausal 205 81 (34.6) 124 (33.4)
Tumor size
T1-T2 471 189 (80.8) 282 (76.0) 0.170
T3-T4 134 45 (19.2) 89 (24.0)
Nodal stage
N2 321 139 (59.4) 182 (49.1) 0.013 *
N3 284 95 (40.6) 189 (50.9)
ER status
Negative 285 112 (47.9) 173 (46.6) 0.767
Positive 320 122 (52.1) 198 (53.4)
PR status
Negative 229 92 (39.3) 137 (36.9) 0.555
Positive 376 142 (60.7) 234 (63.1)
HER2 status
Negative 376 136 (58.1) 240 (64.7) 0.105
Positive 229 98 (41.9) 131 (35.3)
Breast cancer subtype
Luminal A 295 107 (45.7) 188 (50.7) 0.368
Luminal B 130 53 (22.6) 77 (20.8)
HER2 positive 99 45 (19.3) 54 (14.5)
Triple negative 81 29 (12.4) 52 (14.0)
Number of NLNs
0-12 477 180 (76.9) 297 (80.0) 0.358
12-39 128 54 (23.1) 74 (20.0)
LNR
< 0.20 42 29 (12.4) 13 (3.5) < 0.001*
0.21-0.65 337 131 (56.0) 206 (55.5)
> 0.65 226 74 (31.6) 152 (41.0)
PMRT, post-mastectomy radiotherapy; ER, estrogen receptor; PR, progesterone
receptor; HER2, human epidermal growth factor receptor-2; NLNs, negative
lymph nodes; LNR, lymph node ratio.
*p < 0.05 indicates a significant difference.
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X-ray with opposed tangential fields or 6–9 Mev elec-
tron beam, with the use of tissue compensation mem-
brane of 0.5–1 cm when needed. Single-field irradiation
was performed for the supra- and infra-clavicular lymph
drainage regions with 6 MV X-ray combined with 12–15
Mev. Patients with tumours positive for the ER or PR (or
both) received endocrine therapy, mainly with tamoxifen
or aromatase inhibitors.
Follow-up and survival endpoints
Follow-up was performed once every 3 to 6 months.
Locoregional recurrence-free survival (LRFS) was the pri-
mary endpoint. Distant metastasis-free survival (DMFS),
disease free survival (DFS), and overall survival (OS) were
the secondary endpoints. Locoregional recurrence refers
to pathologically confirmed recurrence at the ipsilateral
chest wall, supraclavicular and subclavian lymph nodes,
axillary lymph nodes, or internal mammary lymph nodes.
Distant metastasis refers to recurrence at a site distant
from the primary cancer based on two imaging examina-
tions or by pathologic assessment. OS was calculated as
the time from the date of diagnosis to the date of death
from any cause or to the date of last follow-up.
Statistical analysis
All data were analyzed using the SPSS statistical software
package (version 16.0; IBM Corporation, Armonk, NY,
USA). The χ2 and Fisher’s exact probability tests were
used to analyze differences in the qualitative data. Cut-
off point analyses were then performed to determine
whether there was a cut-off NLN number that was re-
lated to the greatest difference in LRFS. The optimum
cut-off point for the NLNs was determined by use of the
receiver operating characteristic (ROC) curve. Calcula-
tion of survival rates were plotted by the Kaplan-Meier
method and compared using the log-rank test. To deter-
mine the effect of the number of NLNs on LRFS, we
performed univariate and multivariate Cox regression mo-
del analysis. The variables with p-values less than 0.05 by
univariate analyses were included in the multivariate ana-
lyses. A p-value less than 0.05 was considered statistically
significant.
Results
Patient clinicopathologic data and status of lymph node
dissection
A total of 605 patients were enrolled and 371 patients
(61.3%) underwent PMRT. Table 1 shows the clinicopa-
thologic data of the enrolled patients. Except for the
greater use of PMRT in patients with pN3 disease, there
were no significant differences between the PMRT and
non-PMRT groups.The median number of RLNs in the entire cohort was
18 (range: 10–73); the median number in the non-PMRT
group and the PMRT group were 18 (range: 10–45) and
18 (range: 10–73), respectively. The median number of
NLNs in the non-PMRT group and the PMRT group was
8 (25th percentile: 5, 75th percentile: 12; range, 0–39) and
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respectively.Survival
The median follow-up time of all patients was 54 months
(range: 6–138 months). A total of 91 patients had lo-
coregional recurrence, and the 5-year LRFS and 8-year
LRFS were 83.3% and 79.8%, respectively. Two hundred
forty-seven patients had distant metastases and the 5-year
DMFS and 8-year DMFS were 58.3% and 50.0%, respec-
tively. The 5-year DFS and 8-year DFS were 55.1% and
46.8%, respectively. One hundred ninety-six patients died
and the 5-year OS and 8-year OS of these patients were
69.9% and 57.9%, respectively.Identification of optimal cut-off points of NLNs
The optimal cut-off points of NLNs were analyzed for
non-PMRT patients using ROC curve. The results showed
that 12 was the optimal cut-off point for NLNs (Area
Under roc Curve = 0.644, p = 0.001) (Figure 1). Therefore,
the optimal cutoff value of 12 was validated as a prognos-
tic factor for analysis of the clinical effect of the number
of NLNs.
The NLN count was associated with pT stage (p = 0.003),
pN stage (p < 0.001), and LNR (p < 0.001), but was not
associated with age, menstrual status, ER status, PR sta-
tus, HER2 status, and BCS (all, p > 0.05) (Additional file 1:
Table S1).Figure 1 The receiver operating characteristic curve of the
optimum cut-off point for the NLNs.Analysis of prognostic factors affecting LRFS in patients
without PMRT
Univariate analysis of non-PMRT patients showed that the
NLN count, LNR, menstruation status, pT stage, and pN
stage were prognostic factors that affected LRFS (p < 0.05)
(Table 2).
Multivariate analysis showed that the number of NLNs
was an independent prognostic factor for LRFS. Pa-
tients with a higher number of NLNs had a better LRFS
(hazard ratio [HR]: 0.132, 95% confidence interval [CI]:
0.032-0.547, p = 0.005), but pN stage and LNR did not
affect LRFS (p > 0.05). In addition, menopausal status
and pT stage were also independent risk factors for LRFS
(p < 0.05 for both) (Table 2).
In patients without PMRT, a higher number of NLNs
was correlated with a better LRFS (p < 0.001), DMFS
(p = 0.017), DFS (p = 0.003), and OS (p = 0.012) using the
log-rank test (Figure 2).
Prognostic value of the number of NLNs in patients
undergoing PMRT
Compared to non-PMRT patients, PMRT patients had bet-
ter outcomes, with significantly improved LRFS (p < 0.001),
DMFS (p = 0.012), DFS (p = 0.001), and OS (p = 0.013)..
Subgroup analysis showed that different numbers of
NLNs could predict the outcome in patients received
PMRT. PMRT improved the LRFS (p < 0.001), DMFS
(p = 0.018), DFS (p = 0.001), and OS (p = 0.008) of patients
with 12 or fewer NLNs. However, PMRT had no effect
on LRFS (p = 0.500), DMFS (p = 0.204), DFS (p = 0.199),
and OS (p = 0.653) of patients with more than 12 NLNs
(Table 3 and Figure 3).
We examined the prognostic effect of the number of
NLNs according to local (chest wall) or regional (regional
lymph node) recurrences in patients with and without
PMRT. In patients with 12 or fewer NLNs, PMRT did not
improved the chest wall recurrence, the 8-year chest wall
recurrence-free survival was 84.7% and 89.8%, respectively
(p = 0.221). However, PMRT improved the regional recur-
rence with the 8-year regional recurrence-free survival
was 90.1% and 70.1%, respectively (p < 0.001). In patients
with more than 12 NLNs, PMRT without any effect on
survival of chest wall recurrence (p = 0.803) and regional
recurrence (p = 0.331).
Discussion
In the present study, we investigated the prognostic
value of the number of NLNs in breast cancer patients
with four or more positive lymph nodes. The results in-
dicate that the number of NLNs can be used to predict
the outcome of PMRT in breast cancer patients.
Total number of RLNs include positive lymph nodes,
so use of this number may only have limited prognostic
value in identification of breast cancer patients that
Table 2 Univariate and multivariate analysis of factors associated with locoregional recurrence free survival in patients
without postmastectomy radiotherapy
Characteristic Univariate analysis Multivariate analyses
HR 95% CI p HR 95% CI p
Age, years (<35 vs. ≥35) 0.707 0.302-1.656 0.425 — — —
Menopausal status (premenopausal vs. postmenopausal) 0.473 0.244-0.919 0.027* 0.494 0.254-0.961 0.038*
Tumor size (T3-T4 vs. T1-T2) 2.708 1.529-4.797 0.001* 2.193 1.231-3.909 0.008*
Nodal stage (N3 vs. N2) 1.991 1.160-3.418 0.012* 1.577 0.762-3.264 0.219
ER status (positive vs. negative) 0.891 0.516-1.530 0.676 — — —
PR status (positive vs. negative) 1.278 0.700-2.222 0.452 — — —
HER2 status (positive vs. negative) 1.032 0.595-1.790 0.912 — — —
Breast cancer subtype
(luminal B vs. luminal A) 1.309 0.676-2.533 0.424 — — —
(HER2 positive vs. luminal A) 0.855 0.368-1.988 0.716 — — —
(triple negative vs. luminal A) 1.409 0.632-3.137 0.402 — — —
Number of NLNs, n (12–39 vs. 0–12) 0.111 0.027-0.458 0.002 0.132 0.032-0.547 0.005
LNR
(0.21-0.65 vs. < 0.20) 3.608 0.859-15.152 0.080 2.950 0.646-13.465 0.163
(> 0.65 vs. < 0.20) 7.473 1.759-31.755 0.006* 3.376 0.773-14.750 0.106
ER, estrogen receptor; PR, progesterone receptor; Her-2, human epidermal growth factor receptor-2; NLNs, negative lymph nodes; LNR, lymph nodes ratio.
*p < 0.05 indicates a significant difference.
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that the number of NLNs is an independent risk factor
for LRFS; the LRR of patients with 10 or more NLNs
was significantly lower than that of patients with fewer
than 10 NLNs, and the difference was especially signi-
ficant in patients with positive lymph nodes [9]. Kuru re-
ported better OS of patients with more than 15 NLNs
[10]. We used Cox multivariate analysis, with NLN
count, LNR, and pN stage as covariates, and found that
the number of NLNs was an independent prognostic
factor for LRFS, but that LNR and pN stage had no sig-
nificant effect on prognosis. These results suggest that
the number of NLNs may be a better indicator of axil-
lary lymph node status in breast cancer patients.
At present, the mechanism underlying why the num-
ber of NLNs can be used to predict the survival of breast
cancer patients is still unclear. However, previous studies
showed that this relationship might be explained by
“stage migration” or by the host’s immune response to
tumor cells and the molecular biology of tumor cells
[15-17]. For example, a study of colorectal cancer pa-
tients found that the lymphocyte response to the tumor
was related to patient survival [18].
The LRR of breast cancer is an important factor used
to guide the selection of PMRT. The status of axillary
lymph nodes has been always one of the main factors
used to guide selection of PMRT. PMRT remains the
standard therapy for breast cancer patients who have
four or more positive lymph nodes. PMRT can elimin-
ate residual occult lesions in the ipsilateral chest walland lymph drainage area, and thereby improve survival.
PMRT improves the prognosis of breast cancer patients
with 4 or more positive axillary lymph nodes [19]. Our
subgroup analysis showed that the LRR was relatively
low in patients with a higher number of NLNs, and that
PMRT provided no obvious benefit for these patients.
In addition, we also found that PMRT improved locore-
gional control by reducing nodal recurrences but without
any effect on local control in the chest wall in patients
with a fewer number of NLNs. This supports our hypo-
thesis that patients with fewer NLNs may have more re-
sidual lesions, which increases the rate of locoregional
recurrence. However, for patients with more NLNs, sur-
gery can reduce the number of residual lesions, and these
patients do not benefit significantly from PMRT.
The American College of Surgeons Oncology Group
(ACOSOG) Z0011 trial reported that axillary lymph node
dissection did not affect the local recurrence and survival
rates of patients without positive sentinel lymph nodes
or with 1–2 positive sentinel lymph nodes after breast-
conserving therapy [20,21]. Thus, axillary lymph node
dissection is unnecessary in these patients [20,21]. How-
ever, the St. Gallen International Breast Cancer Confer-
ence (2013) reported that axillary lymph node dissection
was necessary for cases who did not receive radiotherapy
and for those with 3 or more metastases in the sentinel
lymph nodes [11]. Thus, the status of axillary lymph nodes
is an important indicator that affects the prognosis of
breast cancer patients and is useful in guiding therapy.
In the present study, the number of NLNs significantly
Figure 2 Impact of the number of negative lymph nodes on the locoregional recurrence-free survival (A), distant metastases-free
survival (B), disease-free survival (C), and overall survival (D) of patients with and without postmastectomy radiotherapy.
Table 3 Impact of the number of negative lymph nodes on locoregional recurrence-free survival in patients with and
without postmastectomy radiotherapy
Survival endpoint 0-12 NLNs (%) 13-39 NLNs (%)
Without PMRT With PMRT p Without PMRT With PMRT p
LRFS (8-year) 61.9 85.6 <0.001* 92.8 92.1 0.500
DMFS (8-year) 42.1 49.3 0.018* 59.9 66.2 0.204
DFS (8-year) 36.5 46.9 0.001* 57.1 42.0 0.199
OS (8-year) 49.1 58.5 0.008* 72.3 68.2 0.653
PMRT, postmastectomy radiotherapy; NLNs, negative lymph nodes; LRFS, locoregional-recurrence-free survival; DMFS, distant metastasis-free survival; DFS, disease
free survival; OS, overall survival.
*p < 0.05 indicates a significant difference.
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Figure 3 Impact of postmastectomy radiotherapy on locoregional recurrence-free survival (A), distant metastases-free survival (B),
disease-free survival (C), and overall survival (D) of patients with 12 or fewer NLNs.
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come of radiotherapy. Therefore, when the status of axil-
lary lymph nodes can be accurately determined, axillary
lymph node dissection is a very important procedure for
patients with positive axillary lymph nodes. In particu-
lar axillary lymph node dissection can reduce the risk of
occult lesions, allows some patients to omit radiotherapy
and thereby avoid radiation injury [22-24], and thereby
improves patient quality of life and prolongs survival.
We need to recognize the limitations of the present
study. First, this study is a single-center retrospective
study and is not representative of the breast cancerpopulation at large. In addition, the optimal number of
NLNs in present study is different from the number in
other studies. This may be related to differences in the
clinical characteristics of the patient populations, use of
different surgical procedures, and analysis by different
statistical method. However, based on the relationship
between the number of NLNs and host immune response
[16,17], sufficient attention should be paid to differences
in individual patient immune status. Ultimately, multi-
center prospective studies should be performed to verify
the value of the number of NLNs in breast cancer patients
to determine the most appropriate cut-off point. Finally,
Wu et al. Radiation Oncology  (2014) 9:284 Page 8 of 9patients enrolled in the current study did not undergo
trastuzumab therapy. Recent studies reported that trastu-
zumab reduces the rate of locoregional recurrence [25,26].
Conclusions
In conclusion, the results of the present study show that
the number of NLNs is a prognostic factor for LRFS in
breast cancer patients with four or more positive lymph
nodes after mastectomy. Patients with more NLNs have
lower LRR, and the number of NLNs can predict the
outcome of PMRT. PMRT might represent for certain
patients with a lower number of NLNs, but not in pa-
tients with a higher number of NLNs. Future prospec-
tive studies are needed to confirm these results.
Additional file
Additional file 1: Table S1. Characteristics of breast cancer patients
according to different number of negative lymph nodes in patients
without postmastectomy radiotherapy.
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